WO2018143552A2 - 탈모방지 또는 발모촉진용 주사용 조성물 - Google Patents
탈모방지 또는 발모촉진용 주사용 조성물 Download PDFInfo
- Publication number
- WO2018143552A2 WO2018143552A2 PCT/KR2017/013759 KR2017013759W WO2018143552A2 WO 2018143552 A2 WO2018143552 A2 WO 2018143552A2 KR 2017013759 W KR2017013759 W KR 2017013759W WO 2018143552 A2 WO2018143552 A2 WO 2018143552A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- keratin
- hair
- pharmaceutical composition
- hair growth
- hair loss
- Prior art date
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 69
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 30
- 230000004936 stimulating effect Effects 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title description 2
- 102000011782 Keratins Human genes 0.000 claims abstract description 177
- 108010076876 Keratins Proteins 0.000 claims abstract description 177
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 40
- -1 dextran sulfate Polymers 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 29
- 108060000903 Beta-catenin Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 102000015735 Beta-catenin Human genes 0.000 claims description 25
- 102000004157 Hydrolases Human genes 0.000 claims description 23
- 108090000604 Hydrolases Proteins 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 23
- 230000001737 promoting effect Effects 0.000 claims description 22
- 239000004698 Polyethylene Substances 0.000 claims description 21
- 229920000573 polyethylene Polymers 0.000 claims description 21
- 230000003660 hair regeneration Effects 0.000 claims description 20
- 230000001965 increasing effect Effects 0.000 claims description 20
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 16
- 102000000905 Cadherin Human genes 0.000 claims description 13
- 108050007957 Cadherin Proteins 0.000 claims description 13
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 13
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 13
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 claims description 12
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 10
- 230000002500 effect on skin Effects 0.000 claims description 10
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 9
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 9
- 102100040120 Prominin-1 Human genes 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 8
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 claims description 8
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 8
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 239000011324 bead Substances 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 150000003505 terpenes Chemical class 0.000 claims description 8
- 108010067770 Endopeptidase K Proteins 0.000 claims description 7
- 102100023371 Forkhead box protein N1 Human genes 0.000 claims description 7
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 claims description 7
- 101000907576 Homo sapiens Forkhead box protein N1 Proteins 0.000 claims description 7
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 claims description 7
- 108090000028 Neprilysin Proteins 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 229920003169 water-soluble polymer Polymers 0.000 claims description 7
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 6
- 102000003729 Neprilysin Human genes 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000000783 alginic acid Substances 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 150000004781 alginic acids Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 6
- 229920002401 polyacrylamide Polymers 0.000 claims description 6
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 5
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 206010033675 panniculitis Diseases 0.000 claims description 5
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 229960000633 dextran sulfate Drugs 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- 150000003462 sulfoxides Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 abstract description 17
- 201000004384 Alopecia Diseases 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 15
- 230000003676 hair loss Effects 0.000 abstract description 12
- 208000024963 hair loss Diseases 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 239000002269 analeptic agent Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 91
- 210000004209 hair Anatomy 0.000 description 58
- 239000000243 solution Substances 0.000 description 49
- 238000002360 preparation method Methods 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 23
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 21
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical group [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000000442 hair follicle cell Anatomy 0.000 description 5
- 230000003659 hair regrowth Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000000984 immunochemical effect Effects 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 230000008823 permeabilization Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000004918 root sheath Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006628 dp medium Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000009461 vacuum packaging Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GNQSEISTGYFZSL-UHFFFAOYSA-N 3-hydroxy-2-imino-6-phenoxypyrimidin-4-amine Chemical compound N=C1N(O)C(N)=CC(OC=2C=CC=CC=2)=N1 GNQSEISTGYFZSL-UHFFFAOYSA-N 0.000 description 1
- OGEDVOVTPTVSEO-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methoxymorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(CCOCC2)OC)=N1 OGEDVOVTPTVSEO-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101150112982 Itga6 gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMNTUASVUKNVJS-UHFFFAOYSA-N Ponceau S (acid form) Chemical compound OC1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C=CC2=C1N=NC(C(=C1)S(O)(=O)=O)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 KMNTUASVUKNVJS-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000207961 Sesamum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001504 poly(N-isopropylacrylamide-co-acrylic acid) Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- YJWSBMQTQRNKPO-UHFFFAOYSA-M sodium;dodecyl sulfite Chemical compound [Na+].CCCCCCCCCCCCOS([O-])=O YJWSBMQTQRNKPO-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21064—Peptidase K (3.4.21.64)
Definitions
- the present invention relates to an injectable composition for preventing hair loss or promoting hair growth comprising keratin.
- Hair loss refers to a condition in which hair is normally missing and genetic factors are known as the main causes. Recently, hair loss population is gradually increasing due to social stress, westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing, and poor scalp management. However, no clear cause for hair loss has yet been identified, and in recent years, more and more people are suffering from alopecia, and their age is decreasing.
- Conventional alopecia treatment methods include formulations based on female hormones in relation to hormonal theory, but there have been reports of skin inflammation, side effects caused by hormone administration, etc., and are currently discontinued.
- Representative hair regrowth recently used, it was first developed and used to promote blood circulation, and it is known to have a hair growth effect as a side effect among patients using it, and then as a raw material for hair regrowth, the US Food and Drug Administration (FDA) Minoxidil (6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine) of U.S. Patent No. 3,382,247 and U.S. Patent No. 5,215,894 approved by U.S. Pat. finasteride).
- FDA Food and Drug Administration
- Patent Document 1 US Patent No. 3,382,247
- Patent Document 2 US Patent No. 5,215,894
- the present inventors have been researching new therapeutic agents that can replace existing hair regrowth agents, and have confirmed that keratin may promote hair growth and prevent hair loss, and further, keratin skin When injected into the tissue was confirmed that the hair growth promoting or hair loss prevention effect is superior to when applied to the skin to complete the present invention.
- an object of the present invention to provide an injectable pharmaceutical composition for preventing hair loss or promoting hair growth comprising keratin.
- an injectable pharmaceutical composition for preventing hair loss or promoting hair growth comprising keratin.
- the keratin may be a keratin bound to a hydrolyzed keratin or a water-soluble polymer.
- the hydrolyzed keratin may have a molecular weight of 500 to 10,000 Daltons (Dalton).
- the water-soluble polymer is hyaluronic acid (hyaluronic acid), polyethylene glycol (PEG), alginic acid (alginic acid), pectin, carrageenan, chondroitin sulfate (chondroitin sulfate), dextran sulfate, chitosan, Polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, dextran, agarose, pullulan, polyacrylamide (PAAm), poly (N-isopropyl) Acrylamide-co-acrylic acid) (P (NIPAAm-co-AAc)), poly (N-isopropyl acrylamide-co-ethylmethacrylate) P (NIPAAm-co-EMA), polyvinylacetate / polyvinyl alcohol (PVAc / PVA), poly (N-vinyl pyrrolidone) (PVP), poly (methylmethacrylate-co-hydroxyethyl methacrylate) (P
- the keratin may promote hair regeneration.
- the pharmaceutical composition is beta catenin (beta catenin), Sox-9, Sox-2, Alkalkine phosphatase, CD133, FGF7, FGF10, BMP6, P-cadherin, E-cadherin, MSX2, FOXN1 and CD10 selected from the group consisting of The amount of abnormal expression can be increased.
- the pharmaceutical composition may be administered to the dermal layer or subcutaneous tissue.
- the pharmaceutical composition may additionally include a penetration enhancer.
- the hydrolyzed keratin is reacted with S1) hydrolase and keratin; And S2) removing the hydrolase, and may be prepared through a method for preparing hydrolyzed keratin.
- the hydrolase may be proteinase-K.
- the hydrolase may be immobilized on the beads.
- the method for preparing hydrolyzed keratin may further include, after step S2), removing the activity of S3) hydrolase.
- Injectable pharmaceutical compositions comprising the keratin of the invention promote hair growth and hair follicle formation.
- the pharmaceutical composition for injection containing keratin according to the present invention has an effect of promoting hair growth or preventing hair loss when applied to skin when injected into skin tissue.
- the pharmaceutical composition of the present invention can be used as a therapeutic agent for preventing hair loss or promoting hair growth.
- Figure 2 is a diagram showing the hair growth effect after two weeks after the injection of Examples 1 to 6 in the hair removed mice.
- FIG. 3 is a photograph showing the degree of hair follicle formation by injecting Examples 1 to 6 into the hair-removed mice and staining with hematoxylin-eosin 2 weeks later.
- Figure 4 is a graph showing the number of hair follicle formation at each stage of hair growth after 2 weeks of injection of Examples 1 to 6 in the dehaired mice.
- 5 is a graph showing the size of hair follicles formed after two weeks of injection of Examples 1 to 6 in the hair removed mice.
- FIG. 7 is a diagram confirming that the proliferation of cells is inhibited when keratin is treated to human hair root cells.
- FIG. 8 is a photograph showing that keratin is adhered to the cell surface by analyzing the interaction with cells when keratin is treated to human hair root cells, thereby inducing cell aggregate formation by keratin.
- FIG. 10 is a diagram showing that when the keratin is treated to human hair root cells, the expression of FGF7, FGF10 and BMP6, which are known as factors for inducing hair growth, is increased.
- FIG. 11 shows the expression of CD34, a molecule that increases the expression of beta catenin and P-cadherin, which are factors related to cell migration and differentiation into Matix cells, and decreases differentiation when keratin is treated to human appearance myocytes. This is a picture confirming the decrease.
- FIG. 12 is a graph showing that when keratin is treated to human appearance myocytes, gene expression of MSX2, FOXN1 and CD10, which are factors related to differentiation into Matix cells, is increased and expression of KRT5 and ITGA6, which are molecules that decrease expression during differentiation, is decreased. to be.
- FIG. 13 shows an increase in the expression of beta catenin molecules and Sox-9 molecules involved in stem cellity, which are factors related to cell migration and clonal activity when hydrolyzed keratin is treated to hairy root cells. It is confirmed that the.
- FIG. 14 is a graph showing that the expression of the Sox-9 gene and the beta-catenin gene involved in stem cell culture was increased when hydrolyzed keratin was treated to external myocytes.
- 15 is a diagram confirming that beta-catenin molecules are expressed more than four-fold when hydrolyzed keratin is treated to external myocytes.
- FIG. 16 is a diagram showing that when hydrolyzed keratin is treated to human hair papilla cells, the formation of cell aggregates related to hair regeneration and stem cell growth is increased by 5 times or more.
- Figure 17 is a photograph confirming that the activity of alkaline phosphatase (alkaline phosphatase) is expressed when hydrolyzed keratin to human Moudu cells.
- the present invention provides an injectable pharmaceutical composition for preventing hair loss or promoting hair growth comprising keratin.
- the keratin may be an intrinsic keratin constituting hair, fleece, feather, horn, nail, horseshoe, or the like, and may be keratin present in skin, nerve tissue, or the like.
- the keratin contains amino acids such as glutamic acid, arginine and cystine, and may particularly contain a high content of cystine.
- the keratin may be any keratin commercially available, may be in the form of processed so as to be dissolved in water or an aqueous solvent, preferably keratin derived from human hair, and has a molecular weight of 40,000 to 70,000 Daltons May be).
- the keratin may be a hydrolyzed keratin or keratin bound to a water soluble polymer.
- the hydrolyzed keratin is a protein that shows the water solubility of the insoluble natural keratin while maintaining the properties of the keratin, and can be used in combination with a keratin-derived peptide.
- the hydrolyzed keratin may be prepared by hydrolysis of keratin by acid, alkali, oxygen or hydrolase, but is not limited thereto, and may be used to prepare hydrolyzed keratin having a molecular weight of 500 to 10,000 Daltons from natural keratin. It can be obtained by conventional methods.
- the hydrolyzed keratin is reacted with S1) hydrolase and keratin; And S2) removing the hydrolase, and may be prepared through a method for preparing hydrolyzed keratin.
- Step S1) is a step of preparing hydrolyzed keratin from keratin using a hydrolase.
- the hydrolase is classified into enzymes that catalyze the hydrolysis reaction when the enzymes are systematically classified, and are classified into nine groups according to the action targets.
- the hydrolase is an enzyme capable of hydrolyzing natural keratin due to the nature of keratin protein, preferably an enzyme that acts on peptide bonds.
- the enzyme acting on the peptide bond may be any one selected from among proteolytic enzymes including leusilaminopeptidase, carboxyptidase, pepsin, trypsin and chymotrypsin. More preferably proteinase-K, but is not limited thereto.
- the yield of hydrolyzed keratin that exhibits a hair loss prevention or hair growth promoting effect may be insufficient if the step S1) is lacking or is not performed properly.
- step S2 is to obtain only hydrolyzed keratin from the hydrolase and hydrolyzed keratin mixture.
- the hydrolase may be immobilized on the beads.
- the hydrolase may be separated from the hydrolyzed keratin according to the physical / chemical properties of the beads by using the difference in magnetic properties of the beads, the difference in weight, or the difference in adsorption or the like.
- the beads are poly-L-lactic acid (PLLA), poly-lactic acid-glycolic acid copolymer (PLGA), polyglycolic acid (PGA), polyurethane (PU), polymethylmethacryl (PMMA), polyethylene (PE) and It may be one or more selected from the group consisting of ferromagnetite, but is not limited thereto.
- the beads may be agarose beads.
- the purity of the hydrolyzed keratin, which exhibits hair growth promoting or hair loss prevention effect, may be lowered when the step S2) is insufficient or is not performed properly.
- the method for preparing hydrolyzed keratin may further comprise the step of removing the activity of the hydrolase S3) after the step S2).
- Step S3) is to stop the hydrolysis of keratin by removing the activity of the hydrolase, and may be left for several hours at a high temperature so that the hydrolase does not react with the keratin.
- the purity of the hydrolyzed keratin may be increased when the step S3) is included, and hydrolyzed keratin having a uniform molecular weight may be obtained.
- the hydrolyzed keratin is added to human hair in a mixture of chloroform and methanol in a ratio of 2: 1 to remove lipids, stirred for 12 hours in a 2% peracetic acid solution, and then 5% 2-mercapto. It can be obtained by adding to ethanol, 5 M urea, 2.6 M thiourea and 25 mM Tris-HCl (pH 8.5) and reacting for 50 to 72 hours, but is not limited thereto.
- the water-soluble polymer is hyaluronic acid (hyaluronic acid), polyethylene glycol (PEG), alginic acid (alginic acid), pectin (pectin), carrageenan (carrageenan), chondroitin sulfate (chondroitin sulfate), dextran sulfate (dextran sulfate) ), Chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, dextran, agarose, pullulan, polyacrylamide (PAAm), poly ( N-isopropyl acrylamide-co-acrylic acid) (P (NIPAAm-co-AAc)), poly (N-isopropyl acrylamide-co-ethyl methacrylate) P (NIPAAm-co-EMA), polyvinylacetate Polyvinyl alcohol (PVAc / PVA), poly (N-vinyl pyrrolidone) (PVP), polyvinylacetate
- the polyethylene glycol is, for example, O-methyl-O ⁇ -succinyl polyethylene glycol, dibasic polyethylene glycol, ⁇ , ⁇ -bis (2-carboxyethyl-polyethylene glycol, O, O ⁇ - Bis (2-bromoethyl) polyethyleneglycol, O, O ⁇ -bis (2-chloroethyl) polyethyleneglycol, polyethyleneglycol dimesyl acid, methoxypolyethyleneglycol acetic acid, O- [2- (3-succinylamino) Ethyl] -O ⁇ -methyl-polyethyleneglycol, O- (2-bromoethyl) -O ⁇ -methylpolyethyleneglycol, O- (2-chloroethyl) -O ⁇ -methylpolyethyleneglycol, polyethyleneglycol monomethyl ether mesyl Acid, aldehyde functionalized polyethylene glycol, glycidyl ether functionalized polyethylene glycol, alde
- the molecular weight of the water-soluble polymer may be 1000 Da to 4000 kDa, preferably 2000 Da to 3000 kDa.
- Preferred examples may include hyaluronic acid of 1000 kDa to 4000 kDa or polyethylene glycol of 1000 Da to 20000 Da.
- the keratin may promote hair regeneration.
- the keratin may promote hair regeneration by inducing growth of human hair follicle cells or hair root cells and aggregation of cells.
- promoting hair growth means “promoting hair growth” and / or “hair regeneration”, and “hair regeneration” induces growth or aggregation of human hair root cells or hair root cells. Ultimately, it means that the hair does not easily fall out, and promotes hair follicle formation in the anagen stage, which is an initial stage of hair growth, thereby inducing the formation of new hair follicles, thereby regenerating the hair. In addition, there is an increase in the expression factors involved in the movement of human hair root cells and the activity of the clone or stem cell.
- the pharmaceutical composition according to the present invention can increase the expression level of genes that induce hair regeneration and hair growth contained in human hair follicle cells or hair root cells.
- the gene is at least one selected from the group consisting of beta catenin, Sox-9, Sox-2, Alkalkine phosphatase, CD133, FGF7, FGF10, BMP6, P-cadherin, E-cadherin, MSX2, FOXN1 and CD10 Can be.
- the beta-catenin is a signaling material that regulates the expression of target genes involved in cell proliferation and differentiation by receiving signals from the Wnt protein, and is a substance contained in stem cells to grow into hair. Means a substance related to the migration and clonal activity of.
- Sox-9 is a substance involved in stemmes and means that the gene is expressed in the nucleus of outer root sheath (ORS) and sebaceous gland cells of hair.
- ORS outer root sheath
- the Sox-2 is expressed in embryonic stem cells, plays an important role in maintaining the pluripotency of embryonic stem cells as well as one of the factors for making induced pluripotent stem cells and plays an important role in maintaining their properties as stem cells. It means to be a substance.
- Alkalkine phosphatase is a kind of enzyme, a substance that exists in various parts of the body by various isoenzymes, a substance involved in angiogenesis in the hair matrix during the hair formation process, and means that the substance increases activity when hair growth occurs. .
- the CD133 is present in the outer membrane of the cell, is known as a protein that induces expression as the cell grows, and is a protein of the CD (Cluster of Differentiation) family, meaning a substance capable of expressing the immunological characteristics of hair follicle stem cells. .
- the FGF7 is a keratinocyte growth factor, which means that it is a substance that penetrates the dermis under the epidermis and strongly promotes the growth and proliferation of keratinocytes.
- the FGF10 is a fibroblast growth factor, and means that the substance penetrates the dermis under the epidermis and strongly promotes the growth and proliferation of fibroblasts.
- the BMP6 is a protein that regulates biological activity in various types of cells including neurons, which means that it is a factor that induces hair growth by inducing aggregate formation of human hair root cells.
- the P-cadherin and E-cadherin are cadgerin-based proteins, used to attach cells, have a function of connecting to actin cytoskeleton and assisting their assembly, and acting as signaling molecules that change gene expression of cells. Protein, which is a factor involved in the migration of human hair follicle cells and differentiation into Matrix cells.
- the MSX2, FOXN1, and CD10 may be factors related to differentiation of human hair root cells into matrix cells.
- the pharmaceutical composition may increase the beta-catenin or Sox-9 in the human hair root cells, thereby inducing the migration and clonal activity of the human hair root cells.
- the pharmaceutical composition may promote cell aggregate formation of human hair root cells, and increase cell aggregate formation, thereby inducing hair growth and improving hair regeneration effect.
- the pharmaceutical composition may increase the expression of beta-catenin, Sox-2, Alkalkine phosphatase, CD133, FGF7 and FGF10 in human hair root cells, thereby increasing the stem cell properties of human hair root cells.
- the hair of the back part of the elderly rats with poor body function was cut, and then injected with keratin solution to analyze the density of hair growth and the formation of hair follicles.
- keratin promotes hair follicle formation and hair regeneration. Accordingly, it has been found that keratin may be used in the pharmaceutical composition for injection of hair loss prevention or hair growth.
- the term "injection” refers to the use of a syringe to inject a drug solution into an intradermal, subcutaneous, intramuscular vein or artery.
- the injection may be a subcutaneous injection, but the present invention is not limited thereto.
- the syringe may be used as long as it is a syringe used for subcutaneously administering the pharmaceutical composition of the present invention as well as a general syringe capable of administering a drug solution through a needle.
- the injectable pharmaceutical composition may be in the form of a liquid or dry powder.
- the dry powder for injection may be administered to a subject by reconstitution with one or more selected from the group consisting of water for injection, physiological saline, glucose solution, and amino acid solution when administered to a patient.
- the amount of active ingredient included in the composition of the present invention depends on the condition of the subject to be administered, the desired degree of treatment, and the like. Specifically, the keratin of the present invention is 0.001 to 10 (w / v)%, specifically 0.01 (w / v)% to 5 (w / v)%, more specifically 0.05 to 2 ( w / v)% concentration.
- the composition may further comprise a percutaneous absorption enhancer (penetration enhancer).
- penetration enhancer percutaneous absorption enhancer
- the pharmaceutical composition may be topically administered to a hair loss site or a site to promote hair growth, and preferably to the dermal layer or subcutaneous tissue.
- the dermal layer is the thickest layer under the epidermis, and the vascular system, the nervous system, the lymphatic system, etc. are intricately intertwined, which means that the hair follicles develop and grow and contain the hair root.
- the subcutaneous tissue is a portion between the muscle and the bone under the dermis layer, there are fat cells containing a large amount of fat to give the human body softness, contouring, can be used as energy. It also means that arteries and lymphatic fluid are circulating.
- the present invention is not limited thereto, and may be used in a pharmaceutical composition for injection, and may include a conventional promoter for promoting transdermal absorption of the active ingredient.
- the sulfoxide is selected from the group consisting of dimethyl sulfoxide (DMSO), dimethyl acetamide (DMAC), dimethyl formamide (DMF), and decylmethyl sulfoxide (DCMS). It may be one or more, but is not limited thereto.
- the pyrrolidione may be one or more selected from the group consisting of N-methyl-2-pyrrolidone (NMP) and 2-pyrrolidone (2P), but is not limited thereto.
- the azone may be 2-dodecylazacycloheptan-2-one or laurocapram.
- the percutaneous absorption enhancer may be included in a conventionally acceptable amount in the composition for injection, depending on the type used.
- composition of the present invention may be used alone or in combination with methods for using hormonal therapy, chemotherapy and biological response modifiers to prevent or promote hair loss.
- the present invention comprises the steps of preparing an injectable pharmaceutical composition comprising keratin; And administering the injectable pharmaceutical composition to the subject, thereby providing a method for preventing hair loss or promoting hair growth.
- administration is meant the introduction of certain substances into the subject in a suitable manner.
- the composition is injected into a subject to exhibit the effect of preventing hair loss or hair growth, the administration may be administration of the dermal layer or subcutaneous tissue.
- the pharmaceutical compositions of the present invention vary depending on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed.
- the dosage of the pharmaceutical composition may be appropriately selected by those skilled in the art depending on the patient's condition, weight, degree of disease, drug form, route of administration, and duration, and 0.0001 to 100 mg / kg or It may be administered at 0.001 to 100 mg / kg. Administration may be administered once a day or may be divided several times.
- the dosage does not limit the scope of the invention in any aspect.
- the dosage and concentration may vary depending on the area of human hair growth, and the concentration of the preferred composition is 0.1-100 mg / ml, but is not limited thereto.
- the term "individual” means all animals, such as rats, mice, and livestock, including humans, in whom hair loss symptoms may occur or may occur. Specifically, it may be a mammal including a human.
- Human hair was washed with a mild detergent and then washed several times with distilled water.
- the hairs were placed in a beaker to remove lipids, and the mixture was added to a mixture of chloroform and methanol in a ratio of 2: 1 until the hairs were submerged. After 24 hours, the hair was air-dried after washing several times with distilled water until no solution used for removing lipids remained in the hair.
- 20 g of dried hair was added to 800 mL of 2% acetic acid peroxide (Sigma aldrich) and stirred at 300 rpm for 12 hours at 37 ° C. After 12 hours, the hairs were sieved and washed with distilled water to remove the remaining oxides.
- the hairs were placed in 400 mL Sindai solution (5% 2-mercaptoethanol, 5 M urea, 2.6 M thiourea (or above Sigma aldrich) and 25 mM Tris-HCl (pH 8.5)) at 50 ° C. and 400 rpm. The reaction was carried out for 72 hours under the conditions. The hair solution was then placed in a 50 mL tube and centrifuged for 20 minutes at 3500 rpm. Gather the supernatant was dialyzed using a 12-14 kDa cut-off Spectra / Por ® 4 dialysis membrane (Spectrum). Keratin powder was prepared by freeze-drying the dialysis of the keratin liquid sample.
- dH 2 O was added to a brown vial (10ml, 22 * 48) made of polyethylene terephthalate having a screw cap, and proteinase-K (Proteinase-) derived from Tritirachium album at pH 9.0 and 30 ° C. K, fixed to Eupergit® C, and dissolved by adding 20 mg of Sigma-Aldrich) at a concentration of 2 mg / ml.
- 400 mg of keratin powder prepared according to Preparation Example 1 was weighed with an electronic balance (0.001 g to 620 g, AJ-620E) for measuring the micropart unit coefficient and placed in the vial.
- the vial was placed in a digital drying oven and then egg-shaped white 5x2 mm magnetic stir bar ([B00C3ME4ZA], 1572500 IKAFLON 40, IKA) and a mobile MS-H-S10 10-Channel magnetic stirrer. And stirred at 37 °C 300 rpm for 1 hour.
- the fully hydrolyzed keratin solution was placed in a centrifuge and operated at 250 g for 10 minutes to precipitate and remove Eupergit® C with Proteinase-K immobilization. Only the supernatant was obtained, and then 10 ⁇ l each of the Eppendorf® PCR tubes. The tube was boiled at 99 ° C. for 1 hour on a CFX96 Touch TM Real-Time PCR Detection System instrument to remove proteinase-K activity. Hydrolyzed keratin liquid samples were lyophilized to produce hydrolyzed keratin powders.
- a micropart unit coefficient measurement electronic balance (0.001 g to 620 g, AJ-620E) and placed in a 500 mL Pyrex beaker (ISOLAB, YLS, Germany). 100 mL of tertiary water was added to the beaker and stirred for 24 hours at a speed of 300 rpm using a 40 ⁇ 8 mm magnetic stir bar ([B00C3ME4ZA], 1572500 IKAFLON 40, IKA) and MS-H-S10 10-Channel magnetic stirrer. It was.
- the keratin solution and the combined solution of mPEG and DMTMM were placed in a 500 mL beaker and at room temperature at 500 rpm using a 40 ⁇ 8 mm magnetic stirring rod (1572500 IKAFLON 40, IKA) and MS-H-S10 10-Channel magnetic stirrer. Stirred for 3 days to react the PEG and keratin.
- pegylated keratin PEGylated Keratin
- 20 mg of pegylated keratin was added to 1 mL of the prepared 500 uM H 2 O 2 solution and vortexed for 5 minutes to prepare a pegylated keratin solution containing 500 uM of H 2 O 2 .
- the glass bottle containing the prepared solution was stored in a nylon vacuum packaging machine 150 ⁇ 200 mm (NY / PELLDPE) (80um) using a pneumatic vacuum packaging machine.
- mice Twenty-four C57BL / 6J old mice (Charles River Corp. Inc., Barcelona, Spain) weighing 20-25 g were used as an animal model to verify the hair growth effects of keratin. After anesthetizing the rats with isoflurane, the rats were clipped with a clipper, leaving the telogen stage hair roots, and the hair and hair roots were shaved. The skin was disinfected with a povidone-iodine solution and then wiped with 60% alcohol.
- Example 1 Solution containing keratin obtained from 0.5w / v% of Preparation Example 1 Subcutaneous single injection (300 ⁇ l)
- Example 2 Solution containing keratin obtained from Preparation Example 1 of 1w / v%
- Example 3 Solution comprising hydrolyzed keratin obtained from preparation 2 of 0.5w / v%
- Example 4 Solution containing hydrolyzed keratin obtained from Preparation Example 2 of 1w / v%
- Example 5 Solution containing pegylated keratin obtained from 0.5w / v% of Preparation Example 3-2
- Example 6 Solution containing pegylated keratin obtained from 0.5w / v% of Preparation Example 3-2
- the Examples 1 to 6 showed a very excellent hair regrowth effect compared to the normal control, the Examples 1 to 6 were grown hair uniformly, Examples 1, 2 and 4 The density of the hair was shown to be very dense. Accordingly, when subcutaneous injection of keratin was confirmed to have a more excellent hair growth effect than when applying the skin, the pharmaceutical composition for injection containing keratin according to the present invention was confirmed to have a hair loss prevention and hair growth promoting effect, prevent hair loss And it was confirmed that the hair growth promoting effect is shown quickly.
- the pharmaceutical composition for injection containing keratin of the present invention had a significantly higher anti-hair loss and hair growth promoting effect than that applied to the skin in a conventional formulation for external application of the skin. was high.
- the injection pharmaceutical composition comprising the keratin of the present invention was confirmed that there is no toxicity at the time of subcutaneous injection of the injection pharmaceutical composition containing keratin, through the subcutaneous injection, blood or water in the body after subcutaneous injection No adverse reactions were observed.
- tissue specimens were obtained at the expense of the rats, the normal control group and the positive control group administered with the solutions of Examples 1 to 6, respectively. This was observed by staining with hematoxylin-eosin (hematoxylin and eosin, H & E), and the analysis results are shown in FIGS. 3 to 5.
- hematoxylin-eosin hematoxylin and eosin, H & E
- the rats to which the keratin solution of Example 1 to Example 6 was administered showed that hair follicle formation occurred at a much higher frequency than the normal control group (FIG. 3).
- rats administered the keratin and hydrolyzed keratin solution of Examples 1 to 4 was confirmed to increase the size of the hair follicles compared to mice administered the PEGylated keratin solution of Examples 5 to 6.
- FIG. 4 as a result of analyzing the hair growth step by step, the formation of hair follicles was promoted in the anagen stage, which is an initial stage of hair growth, and the formation of new hair follicles was induced therefrom.
- the concentration of keratin solution administered to the rats increased, the diameter size of the hair follicles tended to increase (FIG. 5).
- SeeBlue® plus2 Pre-Stained Standard (novex) size markers were taken out at room temperature and vortexed to allow the solution to mix thoroughly.
- a total of 40 ⁇ l of the sample was mixed with 10 ⁇ l Bolt TM LDS Sample Buffer (4 ⁇ ), 4 ⁇ l Bolt TM LDS Reducing Agent (10 ⁇ ) and 26 ⁇ l of 4% hydrolyzed keratin.
- a hydrolyzed keratin sample was prepared by setting the temperature of the heating block (HYSC_Introduction_Heating Block_2014) to 100 ° C. and applying heat for 10 minutes.
- the SDS-PAGE analysis showed a protein band at the molecular weight level of about 50k dalton for the extracted natural keratin, but for the hydrolyzed keratin at a molecular weight level of 3-6k dalton It was confirmed that the band appeared smear. It was found that the hydrolyzed keratin was composed of digested peptides of various molecular weights.
- RNA sequencing analysis was performed by applying 1 ⁇ g of RNA to macrogen.
- human hair root cells were inoculated with 5 ⁇ 10 4 cells in 6-well plates and replaced with ORS medium containing ORS medium or 1% (w / v) keratin after 24 hours. After incubation for 3 days, the expression levels of beta catenin, CD34, P-cadherin and E-cadherin and the expression of transcription factors were measured by immunochemical staining and RT-PCR analysis.
- Hybrid-R kit (Gene All) was used for RNA extraction, and the extracted RNA was quantified using a nanodrop (MICROP UV-Vis Spectrophotometer M600). 1 ⁇ g of RNA was added to AccuPower Cycle Script RT Premix (Bioneer, Daejeon, Korea) and cDNA was made using a thermal cycler (T106, Bio-Rad). The sequences of the used primers are shown in Table 2 below.
- ORS Human outer sheath cells were seeded 5 ⁇ 10 4 in 6 well plates and replaced with ORS medium or ORS medium containing 1% (w / v) hydrolyzed keratin after 24 hours. . After incubation for 1, 3 and 5 days, the expression levels of beta catenin, Sox-9 and CD44 were measured by immunochemical staining and RT-PCR analysis.
- RNA extraction was performed three times with DPBS, and the secondary Alexa Fluor 546 conjugated antibody and the secondary Alexa Fluor 488-conjugated antibody were treated at room temperature for 1 hour. Then washed three times with DPBS and treated with 4 ', 6-diamidino-2-phenylindole (DAPI). Then, the stained cells were observed by fluorescence microscope (Olympus I ⁇ 71). Culture medium of cells incubated in 6-well plates for RT-PCR analysis was removed and washed with DPBS. Hybrid-R kit (Gene All) was used for RNA extraction, and the extracted RNA was quantified using a nanodrop (MICROP UV-Vis Spectrophotometer M600).
- DAPI 6-diamidino-2-phenylindole
- RNA 1 ⁇ g was added to AccuPower Cycle Script RT Premix (Bioneer, Daejeon, Korea) and cDNA was made using a thermal cycler (T106, Bio-Rad).
- T106 Thermal cycler
- Sense (5’-3 ’) Antisense (5’-3 ’) beta-catenin TGCAGTTCGCCTTCACTATG (SEQ ID NO: 1) CTGCACAAACAATGGAATGG (SEQ ID NO: 2) Sox-9 ACCAGTACCCGCATCTGCA (SEQ ID NO: 15) TGTTCCGTGGCCTCTTCG (SEQ ID NO: 16) beta-actin GTCAGGCAGCTCGTAGCTCT (SEQ ID NO: 13) TCGTGCGTGACATTAAGGAG (SEQ ID NO: 14)
- sample dye (DTT, sigma 43815, bromophenol blue sigma, BR0222, Glycerl, bioshop, GLY001) was added to 30 ⁇ g protein sample, mixed to 1 ⁇ , the sample was placed in a heating block (HYSC_Introduction_Heating Block_2014), and 95 ° C. Heated at for 10 min.
- Light spin down and vortexing (Stuart Scientific SA8 vortex mixer AC input 90/230 V, 50-60 Hz), left on ice, PROTEAN® Tetra Handcast Systems (Bio-rad) were prepared.
- the glass plate was tilted to remove the ethanol, and then the final 10 ml of stacking gel (30% acrylamide / Bis solution, 19: 1 # 1610154) 1.3 ml, dH2O 6.1 on the separation gel was removed.
- the gel was separated from the gel plate and placed in a transfer buffer.
- the transfer buffer is glycine (Glycine, sigma) 14.4g, Trizma base (sigma, T1503) 3g, methanol (merk) 200mL and d 2 Prepared using 800 ml of OH
- the PVDF transfer membrane (millipore cat No ISEQ 10100 10 cm ⁇ 10 cm PVDF) was soaked for 5 minutes in methanol, 3 minutes in tertiary H 2 O and 3 minutes in transfer buffer.
- Cassette sandwiches were prepared in the following order: (-) black plate-sponge-3M paper-transparent plate transfer device (Bio-rad) The cassette was placed in a water bath and transferred for 90 minutes at 200 V on a stirrer. After transfer, the bands were identified by staining the gel and the membrane 2.5 g of ponceau S and 5 ml of acetic acid were added to dH 2 O to prepare a reagent solution to obtain 500 ml, and then the entire membrane solution was prepared. After shaking for about 5 minutes at and washed 2-3 times with H 2 O to check the band, and marked the ladder size.
- a blocking solution with 10 g of skim milk (BD, 2322100) and 200 ml of TBS (Tris 12g, Nacl9g in d 2 OH), place the membrane in a plastic bowl, and then rinse in 10 ml of blocking solution for 1 hour. During incubation. B-catenin primary antibody (Anti-beta Catenin antibody [E247] (ab32572)) and B-actin primary antibody ( ⁇ -Actin Antibody (C4)) diluted 1: 1000 were added to the 10 ml blocking solution. After that, the cells were incubated for 24 hours at 4 ° C in a Santa Cruz incubator.
- B-catenin primary antibody Anti-beta Catenin antibody [E247] (ab32572)
- B-actin primary antibody ⁇ -Actin Antibody (C4)
- TBST Tris 12g, Nacl 9g in d 2 OH, 1% tween 20
- B-catenin secondary antibody goat anti-rabbit IgG-HRP diluted 1: 10000 in 10 ml of blocking solution) : sc-2004
- B-actin secondary antibody mouse anti-rabbit IgG-HRP
- DP cells Human dermal papilla (DP) cells were inoculated 2 ⁇ 10 5 in 6 well plates treated with nothing. After 24 hours it was replaced with DP medium or DP medium containing 1% (w / v) hydrolyzed keratin. After incubation for 1, 2 and 3 days, the degree of cell aggregate formation and the activity of alkaline phosphatase were analyzed and beta catenin and Sox were analyzed by immunochemical staining. The expression levels of -2, CD133, alkaline phosphatase, FGF7 and FGF10 were measured.
- the number of cell aggregates generated upon treatment of hydrolyzed keratin was measured using an optical microscope during the culturing of human dermal papilla (DP) cells.
- alkaline phosphatase detection kit Alkaline phosphatase detection kit, Merk Millipore SCR004 Wash with rinse buffer, and add 1 ml of Naphthol AS-BI phosphate solution: Fast Red Violet solution: distilled water in a 2: 1: 1 mixture.
- the reaction was carried out at room temperature. After the reaction, the cells stained by the activity of alkaline phosphatase expressing alkaline phosphate cells were observed by fluorescence microscope (Olympus I ⁇ 71).
- rabbit anti-human beta-catenin antibody diluted at 1: 200, mouse anti-human Sox-2 antibody, rat Rabbit anti-human ALPase antibody, rabbit anti-human CD133 antibody, mouse anti-human FGF-7 antibody And rabbit anti-human FGF-10 antibody (rabbit anti-human FGF-7 antibody) was treated for 24 hours at 4 °C. After 24 hours, the reaction was washed three times with DPBS and treated with secondary Alexa Fluor 546 conjugated antibody and secondary Alexa Fluor 488-conjugated antibody for 1 hour at room temperature. It was then washed three times with DPBS and treated with 4 ', 6-diamidino-2-phenylindole (DAPI). Stained cells were observed by fluorescence microscopy (Olympus I ⁇ 71).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
구분 | 성분 | 투여방법 |
정상 대조군 | - | - |
양성 대조군 | 3%의 미녹시딜(minoxidil) | 피부 위에 매일 2주간 도포(도포량 100㎕/cm2) |
실시예 1 | 0.5w/v%의 제조예 1로부터 얻은 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
실시예 2 | 1w/v%의 제조예 1로부터 얻은 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
실시예 3 | 0.5w/v%의 제조예 2로부터 얻은 가수분해된 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
실시예 4 | 1w/v%의 제조예 2로부터 얻은 가수분해된 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
실시예 5 | 0.5w/v%의 제조예 3-2로부터 얻은 페길화된 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
실시예 6 | 0.5w/v%의 제조예 3-2로부터 얻은 페길화된 케라틴을 포함하는 용액 | 피하 단일 주사(300㎕) |
비교예 1 | 1w/v%의 제조예 1로부터 얻은 케라틴을 포함하는 용액 | 피부 위에 도포(도포량 100㎕/cm2) |
Sense(5'-3') | Antisense(5'-3') | |
beta-catenin | TGCAGTTCGCCTTCACTATG(서열번호 1) | CTGCACAAACAATGGAATGG(서열번호 2) |
KRT5 | ACCAGTACCCGCATCTGCA(서열번호 3) | TGTTCCGTGGCCTCTTCG(서열번호 4) |
MSX2 | CCGCCAAGACATATGAGCCC(서열번호 5) | ACCTGGGTCTCTGTGAGGTT(서열번호 6) |
ITGA6 | AGCTGTGCTTGCTCTACCTG(서열번호 7) | CCGGGGTCTCCATATTTCCG(서열번호 8) |
FOXN1 | AGTGGTGCTGGGATGTTCTG(서열번호 9) | ATAGTGTGAGGAGCCCAGGT(서열번호 10) |
CD10 | CTTTAGTGCCCAGCAGTCCA(서열번호 11) | GAGTCCACCAGTCAACGAGG(서열번호 12) |
beta-actin | GTCAGGCAGCTCGTAGCTCT(서열번호 13) | TCGTGCGTGACATTAAGGAG(서열번호 14) |
Sense(5’-3’) | Antisense(5’-3’) | |
beta-catenin | TGCAGTTCGCCTTCACTATG(서열번호 1) | CTGCACAAACAATGGAATGG(서열번호 2) |
Sox-9 | ACCAGTACCCGCATCTGCA(서열번호 15) | TGTTCCGTGGCCTCTTCG(서열번호 16) |
beta-actin | GTCAGGCAGCTCGTAGCTCT(서열번호 13) | TCGTGCGTGACATTAAGGAG(서열번호 14) |
Claims (13)
- 케라틴을 포함하는 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 1항에 있어서,상기 케라틴은 가수분해된 케라틴 또는 수용성 고분자에 결합된 케라틴인 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 2항에 있어서,상기 가수분해된 케라틴은 분자량이 500 내지 10,000달톤(Dalton)인 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 2항에 있어서,상기 수용성 고분자는 히알루론산(hyaluronic acid), 폴리에틸렌글리콜(PEG), 알긴산(alginic acid), 펙틴(pectin), 카라기난(carrageenan), 콘드로이틴 설페이트(chondroitin sulfate), 덱스트란 설페이트(dextran sulfate), 키토산, 폴리리신(polylysine), 콜라겐, 젤라틴, 카르복시메틸 키틴, 피브린(fibrin), 덱스트란(dextran), 아가로스(agarose), 플루란(pullulan), 폴리아크릴아마이드(PAAm), 폴리(N-이소프로필 아크릴아마이드-co-아크릴산)(P(NIPAAm-co-AAc)), 폴리(N-이소프로필 아크릴아마이드-co-에틸메타크릴레이트)P(NIPAAm-co-EMA), 폴리비닐아세테이트/폴리비닐알콜(PVAc/PVA), 폴리(N-비닐 피롤리돈)(PVP), 폴리(메틸메타크릴레이트-co-하이드록시에틸 메타크릴레이트)(P(MMA-co-HEMA)), 폴리(폴리에틸렌글리콜-co-펩타이드(P(PEG-copeptide)), 알지네이트-g-(폴리에틸렌옥사이드-폴리프로필렌옥사이드-폴리에틸렌옥사이드)(alginate-g-(PEOPPO-PEO)), 폴리(폴리라틱산-co-글리콜릭산)-co-세린)(P(PLGA-co-serine)), 콜라겐-아크릴레이트(collagenacrylate), 알지네이트-아크릴레이트(alginate-acrylate), 폴리(하이드록시프로필 메타크릴아마이드-g-펩타이드)(P(HPMA-g-peptide)), 폴리(하이드록시에틸메타크릴레이트/메트리겔)(P(HEMA/Matrigel)), 히알루론산-g-N-이소프로필아크릴아마이드(HA-g-NIPAAm), 폴리에틸렌옥사이드(PEO), 폴리에틸렌옥사이드-폴리프로필렌옥사이드 공중합체(PEO-PPO, Pluronic series), 폴리에틸렌옥사이드-폴리락틱산 공중합체(PEO-PLA), 폴리에틸렌옥사이드-폴리락틱글리콜산 공중합체(PEO-PLGA), 폴리에틸렌옥사이드-폴리카프로락톤 공중합체(PEO-PCL), 폴리옥시에틸렌 알킬 에테르류 (polyoxyethylene alkyl ethers, Brij Series), 폴리옥시에틸렌 케스터 오일 유도체류(polyoxyethylene castor oil derivatives, Cremophores), 폴리옥시에틸렌 소르비탄 지방산 에스터류(polyoxyethylene sorbitan fatty acid esters, Tween Series), 및 폴리옥시에틸렌 스테아레이트류(polyoxyethylene stearates)으로 이루어진 그룹으로부터 선택된 1종 이상인 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 1항에 있어서,상기 케라틴은 모발재생을 촉진하는 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 1항에 있어서,상기 약학 조성물은 베타 카테닌(beta catenin), Sox-9, Sox-2, Alkalkine phosphatase, CD133, FGF7, FGF10, BMP6, P-cadherin, E-cadherin, MSX2, FOXN1 및 CD10 으로 이루어진 그룹으로부터 선택된 1종 이상의 발현양을 증가시키는 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 1항에 있어서,상기 약학 조성물은 진피층 또는 피하조직에 투여되는 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 1항에 있어서,상기 약학 조성물은 경피흡수 촉진제(penetration enhancer)를 추가적으로 포함하는 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 8항에 있어서,상기 경피흡수 촉진제는 술폭시드(sulphoxide), 아존(azone), 피롤리돈(pyrrolidone), 지방산, 탄소수 1 내지 4의 저급 알코올, 탄소수 6 이상의 고급 지방 알코올(fatty alcohol), 글리콜(glycol), 요소(urea), 테르펜(terpene), 테르페노이드(terpenoid), 및 인지질(phospholipid)로 이루어진 그룹으로부터 선택된 1종 이상인 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 2항에 있어서,상기 가수분해된 케라틴은 S1) 가수분해효소와 케라틴을 반응시키는 단계; 및 S2) 상기 가수분해효소를 제거하는 단계를 포함하는, 가수분해된 케라틴의 제조 방법을 통해 제조된 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 10항에 있어서,상기 가수분해효소는 프로테이나제-K인 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 10항에 있어서,상기 가수분해효소는 비드에 고정된 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
- 제 10항에 있어서,상기 가수분해된 케라틴의 제조 방법은 상기 제 S2) 단계 이후에, S3) 가수분해효소의 활성을 제거하는 단계를 추가로 포함하는 것을 특징으로 하는, 탈모방지 또는 발모촉진용 주사용 약학 조성물.
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201906787UA SG11201906787UA (en) | 2017-01-31 | 2017-11-29 | Injectable composition for preventing hair loss or stimulating hair growth |
CA3050087A CA3050087C (en) | 2017-01-31 | 2017-11-29 | Injectable composition containing keratin for preventing hair loss or stimulating hair growth |
MX2019008999A MX2019008999A (es) | 2017-01-31 | 2017-11-29 | Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo. |
EP17894684.4A EP3578194B1 (en) | 2017-01-31 | 2017-11-29 | Injectable composition for preventing hair loss or stimulating hair growth |
RU2019123305A RU2731421C1 (ru) | 2017-01-31 | 2017-11-29 | Инъецируемая композиция для профилактики выпадения волос или стимуляции роста волос |
IL268275A IL268275B2 (en) | 2017-01-31 | 2017-11-29 | An injectable composition for preventing hair loss or encouraging hair growth |
JP2019558317A JP6861298B2 (ja) | 2017-01-31 | 2017-11-29 | 脱毛防止又は発毛促進用注射用組成物 |
US16/481,827 US20200405628A1 (en) | 2017-01-31 | 2017-11-29 | Injectable composition for preventing hair loss or stimulating hair growth |
CN201780084940.5A CN110312519A (zh) | 2017-01-31 | 2017-11-29 | 毛发防脱或毛发促生用注射用组合物 |
BR112019015575-9A BR112019015575A2 (pt) | 2017-01-31 | 2017-11-29 | Composição injetável para evitar perda de cabelo ou estimular crescimento de cabelo |
AU2017397569A AU2017397569B2 (en) | 2017-01-31 | 2017-11-29 | Injectable composition for preventing hair loss or stimulating hair growth |
NZ755295A NZ755295B2 (en) | 2017-01-31 | 2017-11-29 | Injectable composition for preventing hair loss or stimulating hair growth |
ZA2019/04463A ZA201904463B (en) | 2017-01-31 | 2019-07-08 | Injectable composition for preventing hair loss or stimulating hair growth |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170014047 | 2017-01-31 | ||
KR10-2017-0014047 | 2017-01-31 | ||
KR1020170142726A KR101859421B1 (ko) | 2017-01-31 | 2017-10-30 | 탈모방지 또는 발모촉진용 주사용 조성물 |
KR10-2017-0142726 | 2017-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018143552A2 true WO2018143552A2 (ko) | 2018-08-09 |
WO2018143552A3 WO2018143552A3 (ko) | 2018-12-06 |
Family
ID=62453128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/013759 WO2018143552A2 (ko) | 2017-01-31 | 2017-11-29 | 탈모방지 또는 발모촉진용 주사용 조성물 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200405628A1 (ko) |
EP (1) | EP3578194B1 (ko) |
JP (1) | JP6861298B2 (ko) |
KR (1) | KR101859421B1 (ko) |
CN (1) | CN110312519A (ko) |
AU (1) | AU2017397569B2 (ko) |
BR (1) | BR112019015575A2 (ko) |
CA (1) | CA3050087C (ko) |
IL (1) | IL268275B2 (ko) |
MX (1) | MX2019008999A (ko) |
RU (1) | RU2731421C1 (ko) |
SG (1) | SG11201906787UA (ko) |
WO (1) | WO2018143552A2 (ko) |
ZA (1) | ZA201904463B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210346283A1 (en) * | 2019-07-29 | 2021-11-11 | Keramedix Inc. | Injectable composition for preventing hair loss or stimulating hair growth |
CN114096270A (zh) * | 2019-07-25 | 2022-02-25 | 新田明胶株式会社 | 生发剂和包含其的食品或饮品 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101979658B1 (ko) | 2019-01-25 | 2019-05-17 | 주식회사 수아아이 | 순지트를 이용한 탈모 방지 및 발모 촉진용 화장료 조성물 제조 방법 |
KR102400270B1 (ko) * | 2019-09-18 | 2022-05-23 | 주식회사 가피바이오 | 케라틴의 산업적 제조 방법 |
KR20230045317A (ko) | 2021-09-28 | 2023-04-04 | 주식회사 아이코어바이오 | 케라틴, 생분해성 고분자 및 산화질소 전달체를 이용한 나노복합체 및 상기 나노복합체를 포함하는 탈모 예방 및 발모 촉진용 조성물 |
KR102394488B1 (ko) * | 2021-11-25 | 2022-05-04 | (주)헤세드바이오 | 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
KR20230120594A (ko) | 2022-02-08 | 2023-08-17 | 주식회사 케라메딕스 | 탈당화 재조합 케라틴을 포함하는 탈모 치료용 조성물 |
WO2023238416A1 (ja) * | 2022-06-07 | 2023-12-14 | マイキューテック株式会社 | ケラチン微粒子に基づく発毛又は育毛剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3382247A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines |
US5215894A (en) | 1992-02-25 | 1993-06-01 | Merck & Co., Inc. | Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors |
KR20170014047A (ko) | 2015-07-28 | 2017-02-08 | 한국도로공사 | 모바일 카드 또는 이종 교통카드를 이용한 하이패스 단말기, 시스템 및 결제방법 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018736A1 (fr) * | 1992-03-19 | 1993-09-30 | Armand Pardo | Compositions cosmetiques capillaires destinees aux traitements contre la chute des cheveux |
JP3407064B2 (ja) * | 1993-11-13 | 2003-05-19 | サンスター株式会社 | 育毛養毛用食品 |
RO115692B1 (ro) * | 1997-02-27 | 2000-05-30 | Inst National De Cercetare Dez | Solutie injectabila, de uz veterinar |
AU3955299A (en) * | 1998-06-09 | 1999-12-30 | Shionogi & Co., Ltd. | Immune tolerance-inducing agents containing hard keratin or keratin-like substance |
DE19831043A1 (de) * | 1998-07-13 | 2000-01-27 | Deutsches Krebsforsch | Hemmung von Alopezie |
US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6270793B1 (en) * | 1999-09-13 | 2001-08-07 | Keraplast Technologies, Ltd. | Absorbent keratin wound dressing |
JP2001211895A (ja) * | 2000-02-04 | 2001-08-07 | Kenji Kida | 生理活性ペプチドの製造法 |
KR100568600B1 (ko) * | 2003-08-29 | 2006-04-07 | 소망화장품주식회사 | 7-디하이드로콜레스테롤을 함유하는 모발용 조성물 |
CN100371017C (zh) * | 2004-10-29 | 2008-02-27 | 肖应庆 | 生物角蛋白在制药中的应用 |
JP4399341B2 (ja) * | 2004-10-29 | 2010-01-13 | 一丸ファルコス株式会社 | 毛髪処理剤 |
US7579317B2 (en) * | 2005-03-11 | 2009-08-25 | Keratec, Ltd. | Nutraceutical composition comprising soluble keratin or derivative thereof |
US8197865B2 (en) * | 2005-08-09 | 2012-06-12 | Access Business Group International Llc | Methods and compositions for modulating hair growth or regrowth |
US8273702B2 (en) * | 2006-02-17 | 2012-09-25 | Wake Forest University Health Sciences | Wound healing compositions containing keratin biomaterials |
RU2309730C2 (ru) * | 2006-04-18 | 2007-11-10 | Леонид Юрьевич Брежнев | Средство для стимуляции роста волос, его варианты и способ его получения |
CA2704774A1 (en) * | 2007-10-31 | 2009-05-07 | Keratec Limited | Keratin derivatives and methods of making same |
KR20090094709A (ko) * | 2008-03-03 | 2009-09-08 | 손영순 | 발모 촉진용 조성물 |
KR100966902B1 (ko) * | 2009-08-25 | 2010-06-30 | (주)엘큐어 | 모발 건강용 트리트먼트 |
CH703390B1 (de) * | 2011-08-05 | 2012-01-13 | Labo Cosprophar Ag | Auf Haarfollikel-Stammzellen wirkende Zusammensetzung zur Stimulation des Haarwachstums. |
KR101390408B1 (ko) * | 2012-01-06 | 2014-05-27 | 최수영 | 헤어 트리트먼트용 조성물 |
RU2505301C2 (ru) * | 2012-05-05 | 2014-01-27 | Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук | Средство для стимуляции роста волос |
GB201212937D0 (en) * | 2012-07-20 | 2012-09-05 | Dupont Nutrition Biosci Aps | Method |
KR20140056990A (ko) * | 2012-11-02 | 2014-05-12 | 경북대학교 산학협력단 | 바이칼린을 유효성분으로 포함하는 탈모 예방 또는 치료, 또는 발모 촉진용 조성물 |
JP2017516869A (ja) * | 2014-06-04 | 2017-06-22 | ジム バイオサイエンシズ,インコーポレイテッド | 皮膚の質を改善するための組成物及び方法 |
KR101509608B1 (ko) * | 2014-12-29 | 2015-04-07 | 비오엠코스메틱 주식회사 | 두피 및 모발 상태 개선용 조성물 |
KR101746219B1 (ko) * | 2015-01-12 | 2017-06-13 | 경희대학교 산학협력단 | 케라틴과 egcg 복합체를 함유하는 조성물 및 그 제조방법 |
US20160235820A1 (en) * | 2015-02-18 | 2016-08-18 | Cormend Technologies, Llc | Method of injecting a keratin-based material into a target region of the heart |
CN104922734B (zh) * | 2015-05-21 | 2017-11-24 | 东南大学 | 促进心肌修复的可注射壳聚糖复合水凝胶及其制备方法 |
JP6767188B2 (ja) * | 2016-07-22 | 2020-10-14 | 日華化学株式会社 | 頭髪頭皮状態改善用食品組成物 |
KR101706515B1 (ko) * | 2016-12-08 | 2017-02-13 | 경희대학교 산학협력단 | 탈모방지 또는 발모촉진용 주사용 조성물 |
-
2017
- 2017-10-30 KR KR1020170142726A patent/KR101859421B1/ko active IP Right Grant
- 2017-11-29 US US16/481,827 patent/US20200405628A1/en not_active Abandoned
- 2017-11-29 WO PCT/KR2017/013759 patent/WO2018143552A2/ko unknown
- 2017-11-29 RU RU2019123305A patent/RU2731421C1/ru active
- 2017-11-29 CN CN201780084940.5A patent/CN110312519A/zh active Pending
- 2017-11-29 BR BR112019015575-9A patent/BR112019015575A2/pt unknown
- 2017-11-29 AU AU2017397569A patent/AU2017397569B2/en active Active
- 2017-11-29 JP JP2019558317A patent/JP6861298B2/ja active Active
- 2017-11-29 EP EP17894684.4A patent/EP3578194B1/en active Active
- 2017-11-29 CA CA3050087A patent/CA3050087C/en active Active
- 2017-11-29 SG SG11201906787UA patent/SG11201906787UA/en unknown
- 2017-11-29 IL IL268275A patent/IL268275B2/en unknown
- 2017-11-29 MX MX2019008999A patent/MX2019008999A/es unknown
-
2019
- 2019-07-08 ZA ZA2019/04463A patent/ZA201904463B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3382247A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines |
US5215894A (en) | 1992-02-25 | 1993-06-01 | Merck & Co., Inc. | Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors |
KR20170014047A (ko) | 2015-07-28 | 2017-02-08 | 한국도로공사 | 모바일 카드 또는 이종 교통카드를 이용한 하이패스 단말기, 시스템 및 결제방법 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114096270A (zh) * | 2019-07-25 | 2022-02-25 | 新田明胶株式会社 | 生发剂和包含其的食品或饮品 |
US20210346283A1 (en) * | 2019-07-29 | 2021-11-11 | Keramedix Inc. | Injectable composition for preventing hair loss or stimulating hair growth |
Also Published As
Publication number | Publication date |
---|---|
NZ755295A (en) | 2021-10-29 |
EP3578194C0 (en) | 2023-07-26 |
RU2731421C1 (ru) | 2020-09-02 |
ZA201904463B (en) | 2020-03-25 |
AU2017397569A1 (en) | 2019-07-25 |
IL268275A (en) | 2019-09-26 |
MX2019008999A (es) | 2019-12-11 |
IL268275B1 (en) | 2023-08-01 |
KR101859421B1 (ko) | 2018-05-21 |
SG11201906787UA (en) | 2019-08-27 |
AU2017397569B2 (en) | 2021-03-04 |
EP3578194A2 (en) | 2019-12-11 |
JP2020505442A (ja) | 2020-02-20 |
CA3050087C (en) | 2023-07-11 |
BR112019015575A2 (pt) | 2020-05-26 |
EP3578194A4 (en) | 2020-12-23 |
CN110312519A (zh) | 2019-10-08 |
US20200405628A1 (en) | 2020-12-31 |
CA3050087A1 (en) | 2018-08-09 |
IL268275B2 (en) | 2023-12-01 |
JP6861298B2 (ja) | 2021-04-21 |
WO2018143552A3 (ko) | 2018-12-06 |
EP3578194B1 (en) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018143552A2 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
Moshayedi et al. | Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain | |
WO2017123022A1 (ko) | 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀 | |
Turner et al. | The performance of decellularized adipose tissue microcarriers as an inductive substrate for human adipose-derived stem cells | |
Pal et al. | Accelerating full thickness wound healing using collagen sponge of mrigal fish (Cirrhinus cirrhosus) scale origin | |
EP3302509B1 (en) | Placenta-derived matrix and methods of preparing and use thereof | |
WO2016006944A1 (ko) | 진피층 및 표피층을 포함하는 삼차원 배양 피부모델을 제조하는 방법 및 이를 통해 제조된 삼차원 배양 피부모델 | |
KR20120120971A (ko) | 인간 다능성 줄기 세포로부터 인간 멜라닌세포를 제조하는 방법 | |
KR20140115296A (ko) | 모낭 외모낭초로부터 멜라닌세포를 유도하기 위한 방법 및 이식을 위한 제조 | |
WO2021201637A1 (ko) | 제대혈 줄기세포에 의해 고효능의 엑소좀이 고함량으로 분비된 배양액의 제조 방법 및 이의 용도 | |
WO2018105941A2 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
WO2013165120A1 (ko) | 신경능선줄기세포의 배양방법 및 그 용도 | |
WO2015186906A1 (ko) | 건 또는 인대 손상 치유를 위한 자가 및 동종의 지방유래 중간엽줄기세포 조성물 및 이의 제조방법 | |
US20240148937A1 (en) | Adipose-derived hydrogel compositions and methods of use | |
WO2022158816A1 (ko) | 줄기세포 유래 엑소좀, 히알루론산, 및 bdde를 포함하는 피부 주름개선용 필러 조성물 및 이의 제조 방법 | |
WO2022050695A1 (ko) | 세포외기질이 담지된 생체모사 조직 접착성 하이드로젤 패치 | |
WO2022119418A1 (ko) | Gdf-3를 고발현하는 제대혈 줄기세포 분리 및 배양 방법 및 gdf-3의 용도 | |
WO2021101198A2 (ko) | 내재성 전구세포 또는 줄기세포 포집능 및 포집된 세포의 혈관 분화 유도능을 갖는 주입형 하이드로겔 조성물 | |
US20210346283A1 (en) | Injectable composition for preventing hair loss or stimulating hair growth | |
WO2015199416A1 (ko) | 피부 또는 혈관 조직 손상 치료용 약학 조성물 및 이의 이용 | |
WO2023121399A1 (ko) | 피부유래 줄기세포의 배양방법 및 그의 용도 | |
WO2019190175A2 (ko) | 편도 유래 중간엽 줄기세포로부터 운동신경세포의 분화방법 | |
WO2023121400A1 (ko) | 모낭유래 줄기세포의 배양방법 및 그의 용도 | |
WO2024128496A1 (ko) | 줄기세포 유래 엑소좀을 포함하는 피부 노화 억제 조성물 및 이의 제조방법 | |
NZ755295B2 (en) | Injectable composition for preventing hair loss or stimulating hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019558317 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3050087 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017397569 Country of ref document: AU Date of ref document: 20171129 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019015575 Country of ref document: BR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17894684 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2017894684 Country of ref document: EP Effective date: 20190902 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112019015575 Country of ref document: BR Free format text: APRESENTE NOVA VIA DOS DESENHOS, UMA VEZ QUE O DOCUMENTO APRESENTADO TEM 19 PAGINAS E FOI NUMERADO COMO 18 PAGINAS. |
|
ENP | Entry into the national phase |
Ref document number: 112019015575 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190729 |